New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg; peginterferon alfa-2b 100ug; ribavirin 200mg;   - combination - 200mg/100mcg/200mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate dibasic sodium phosphate monohydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection - victrelis pegatron combination therapy is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg; peginterferon alfa-2b 120ug; ribavirin 200mg;   - combination - 200mg/120mcg/200mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 active: peginterferon alfa-2b 120ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection - victrelis pegatron combination therapy is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg; peginterferon alfa-2b 150ug; ribavirin 200mg;   - combination - 200mg/150mcg/200mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 active: peginterferon alfa-2b 150ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection - victrelis pegatron combination therapy is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg; peginterferon alfa-2b 50ug; ribavirin 200mg;   - combination - 200mg/50mcg/200mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 active: peginterferon alfa-2b 50ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection - victrelis pegatron combination therapy is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

united imaging healthcare (australia & new zealand) pty ltd - 45143 - combination diagnostic imaging system, pet/ct - a radiological imaging system that is a combination of a positron emission tomography (pet) camera system for nuclear medicine images, and a computed tomography (ct) camera system for x-ray images. the nuclear medicine images and the x-ray images may be registered and displayed in a fused format (overlaid in the same orientation) for the anatomical localization of the nuclear medicine data. the pet and ct portions of the system may be used independently or in combination. the pet and ct images may be transferred to other systems for radiation therapy planning or additional processing.

Australia - English - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd - 45143 - combination diagnostic imaging system, pet/ct - a radiological imaging system that is a combination of a positron emission tomography camera system for nuclear medicine images, and a computed tomography camera system for x-ray images.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

alfresa pharma corporation - combination gastrointestinal medicine for dispensing composed mainly of the following ingredients:; taka-diastase; magnesium aluminometasilicate - pale gray to grayish brown powder

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - aprepitant 80mg; aprepitant 125mg - combination capsule - 80/125mg - active: aprepitant 80mg excipient: gelatin hyprolose microcrystalline cellulose sodium laurilsulfate sucrose active: aprepitant 125mg excipient: gelatin hyprolose microcrystalline cellulose sodium laurilsulfate sucrose - emend, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: · moderately emetogenic cancer chemotherapy. · highly emetogenic cancer chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - peginterferon alfa-2b 100ug; ribavirin 200mg;   - combination - 200mg + 100µg - active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin hydrated silica lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

schering-plough a division of schering-plough animal health limited - peginterferon alfa-2b 120ug; ribavirin 200mg;   - combination - 200mg + 120µg - active: peginterferon alfa-2b 120ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg   excipient: croscarmellose sodium gelatin hydrated silica lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide